AR and posterior cortical atrophy: Since the androgen receptor (AR) is required for PCa pathogenesis, androgen deprivation therapy has been the principal treatment for aggressive PCa; however, despite the high initial response rates, these tumors ultimately develop resistance, i.e., castration-resistant PCa (CRPC) [79].